Preclinical discovery and development of maraviroc for the treatment of HIV

Ending AIDS — Is an HIV Vaccine Necessary?

(2014) Anthony S. Fauci et al.   NEW ENGLAND JOURNAL OF MEDICINE

HIV-1, human interaction database: current status and new features

(2014) Danso Ako-Adjei et al.   NUCLEIC ACIDS RESEARCH

Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals

(2014) Ai Kawana-Tachikawa et al.   PLoS One

Debate erupts on 'repurposed' drugs for Ebola

(2014) M. Enserink   SCIENCE

Identification of 53 compounds that block Ebola virus-like particle entry via a repurposing screen of approved drugs

(2014) Jennifer Kouznetsova et al.   Emerging Microbes & Infections

Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection

(2013) Maria C. Puertas et al.   AIDS

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1

(2013) David A. Cooper et al.   AIDS

The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial

(2013) P. W. Hunt et al.   BLOOD

Five-Year Safety Evaluation of Maraviroc in HIV-1–Infected Treatment-Experienced Patients

(2013) Roy M. Gulick et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence

(2013) P. Delobel et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial

(2013) Stefano Rusconi et al.   PLoS One

A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

(2013) Michael Roche et al.   Retrovirology

Structure of the CCR5 Chemokine Receptor-HIV Entry Inhibitor Maraviroc Complex

(2013) Q. Tan et al.   SCIENCE

HIV: Cell Binding and Entry

(2013) C. B. Wilen et al.   Cold Spring Harbor Perspectives in Medicine

Improving HIV coreceptor usage prediction in the clinic using hints from next-generation sequencing data

(2012) N. Pfeifer et al.   BIOINFORMATICS

The lowest X4 Geno2Pheno false-positive rate is associated with greater CD4 depletion in HIV-1 infected patients

(2012) M.M. Santoro et al.   CLINICAL MICROBIOLOGY AND INFECTION

Lipids at the interface of virus–host interactions

(2012) Vineela Chukkapalli et al.   CURRENT OPINION IN MICROBIOLOGY

HIV-1 Antiretroviral Resistance

(2012) Michele W. Tang et al.   DRUGS

Safety Profile of Maraviroc in Patients Coinfected With HIV-1 and Hepatitis B or C Included in the Maraviroc Expanded Access Program

(2012) Adriano Lazzarin et al.   HIV CLINICAL TRIALS

Maraviroc Intensification of Stable Antiviral Therapy in HIV-1–Infected Patients With Poor Immune Restoration

(2012) Lise Cuzin et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Vicriviroc plus optimized background therapy for treatment-experienced subjects with CCR5 HIV-1 infection: Final results of two randomized phase III trials

(2012) Marcos M. Caseiro et al.   JOURNAL OF INFECTION

A Pilot Trial of Adding Maraviroc to Suppressive Antiretroviral Therapy for Suboptimal CD4+ T-Cell Recovery Despite Sustained Virologic Suppression: ACTG A5256

(2012) T. J. Wilkin et al.   JOURNAL OF INFECTIOUS DISEASES

Natural evolution of CD4+ cell count in patients with CD4 >350 or >500 cells/mm3at the time of diagnosis according to HIV-1 coreceptor tropism

(2012) Cathia Soulié et al.   JOURNAL OF MEDICAL VIROLOGY

V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc

(2012) Reem Berro et al.   VIROLOGY

Correlation of coreceptor usage and disease progression

(2012) Chris Verhofstede et al.   Current Opinion in HIV and AIDS

Targeting the Human DEAD-Box Polypeptide 3 (DDX3) RNA Helicase as a Novel Strategy to Inhibit Viral Replication

(2011) A. Garbelli et al.   CURRENT MEDICINAL CHEMISTRY

The Relationship of CCR5 Antagonists to CD4+ T-Cell Gain: A Meta-Regression of Recent Clinical Trials in Treatment-Experienced HIV-Infected Patients

(2011) Timothy J. Wilkin et al.   HIV CLINICAL TRIALS

HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism

(2011) M. Roche et al.   JOURNAL OF VIROLOGY

European guidelines on the clinical management of HIV-1 tropism testing

(2011) LPR Vandekerckhove et al.   LANCET INFECTIOUS DISEASES

Pre-Admission Statin Use and In-Hospital Severity of 2009 Pandemic Influenza A(H1N1) Disease

(2011) Stephen J. Brett et al.   PLoS One

Intensification of Antiretroviral Therapy with a CCR5 Antagonist in Patients with Chronic HIV-1 Infection: Effect on T Cells Latently Infected

(2011) Carolina Gutiérrez et al.   PLoS One

A combination of polymorphic mutations in V3 loop of HIV-1 gp120 can confer noncompetitive resistance to maraviroc

(2011) Yuzhe Yuan et al.   VIROLOGY

Long-term mortality in HIV patients virally suppressed for more than three years with incomplete CD4 recovery: A cohort study

(2010) Frederik N Engsig et al.   BMC INFECTIOUS DISEASES

Two-Year Safety and Virologic Efficacy of Maraviroc in Treatment-Experienced Patients With CCR5-Tropic HIV-1 Infection: 96-Week Combined Analysis of MOTIVATE 1 and 2

(2010) W David Hardy et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

New Insights into the Mechanisms whereby Low Molecular Weight CCR5 Ligands Inhibit HIV-1 Infection

(2010) Javier Garcia-Perez et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection

(2010) David A. Cooper et al.   JOURNAL OF INFECTIOUS DISEASES

A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5

(2010) John C. Tilton et al.   JOURNAL OF VIROLOGY

Role of Abl Kinase and the Wave2 Signaling Complex in HIV-1 Entry at a Post-Hemifusion Step

(2010) Brooke Harmon et al.   PLoS Pathogens

Broad usage spectrum of G protein-coupled receptors as coreceptors by primary isolates of HIV

(2009) Nobuaki Shimizu et al.   AIDS

Host proteins involved in HIV infection: New therapeutic targets

(2009) Nathalie Arhel et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE

Lymphoma Diagnosis and Plasma Epstein‐Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211

(2009) Athe M. N. Tsibris et al.   CLINICAL INFECTIOUS DISEASES

A Double‐Blind, Placebo‐Controlled Trial of Maraviroc in Treatment‐Experienced Patients Infected with Non‐R5 HIV‐1

(2009) Michael Saag et al.   JOURNAL OF INFECTIOUS DISEASES

Heterosexual Transmission of Human Immunodeficiency Virus Type 1 Subtype C: Macrophage Tropism, Alternative Coreceptor Use, and the Molecular Anatomy of CCR5 Utilization

(2009) J. Isaacman-Beck et al.   JOURNAL OF VIROLOGY

Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

(2008) Samantha Abel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers

(2008) Samantha Abel et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

A Deletion in the Chemokine Receptor 5(CCR5)Gene Is Associated with Tickborne Encephalitis

(2008) Elin Kindberg et al.   JOURNAL OF INFECTIOUS DISEASES

Genetic Deficiency of Chemokine Receptor CCR5 Is a Strong Risk Factor for Symptomatic West Nile Virus Infection: A Meta‐Analysis of 4 Cohorts in the US Epidemic

(2008) Jean K. Lim et al.   JOURNAL OF INFECTIOUS DISEASES

Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection

(2008) Gerd Fätkenheuer et al.   NEW ENGLAND JOURNAL OF MEDICINE